Chonluten

Chonluten — Bronchial Epithelium Bioregulator

Chonluten is a Khavinson-class short-chain bioregulator peptide that restores youthful gene expression in bronchial epithelium tissue.

Peptide Specifications

Parameter	Value
Sequence	Glu-Asp-Gly
Mass	319.3 g/mol
Purity	>98.0%
Target Organ	Bronchial Epithelium

Figure 1: Chonluten Organ-Specific Bioregulation

Tissue-Specific Mechanism

1. Tripeptide targeting bronchial epithelial gene expression.
2. Normalizes airway epithelial cell differentiation.
3. Restores damaged mucosal barriers.
4. Reduces goblet cell hyperplasia.
5. Supports bronchial basement membrane regeneration.

Figure 2: Bronchial Epithelium Regeneration Curve

Research Results

• 1: Complements Bronchogen targeting epithelial layer.
• 2: Post-infection respiratory recovery models.
• 3: Genetic transcription-level airway integrity.

Bronchial Mucosa Bioregulator

Chonluten (Glu-Asp-Gly) is a synthetic tripeptide bioregulator targeting bronchial mucosal tissue gene expression. While Bronchogen addresses broader respiratory tissue function, Chonluten specifically targets the bronchial mucosa—the specialized epithelial lining that serves as both a physical barrier and an active immune interface in the airways. The bronchial mucosa contains goblet cells (mucus production), ciliated cells (mucociliary clearance), club cells (secretory), and a dense network of submucosal immune cells that represent the first line of respiratory defense.

1. Chonluten modulates goblet cell mucin gene expression, optimizing the balance between protective mucus production and excessive mucus that impairs airflow.
2. Secretory IgA (sIgA) production by mucosal plasma cells is normalized, restoring the primary immunoglobulin defense in airway surface liquid.
3. Tight junction protein expression (occludin, claudin-1, ZO-1) in bronchial epithelium is upregulated, strengthening the mucosal barrier.
4. Club cell secretory protein (CC16) expression is restored, providing anti-inflammatory and immunomodulatory protection in the airways.
5. Antimicrobial peptide expression (defensins, lysozyme) in airway epithelium is normalized, supporting innate microbial defense.

Mucosal Defense Research

• Chronic Bronchitis: In chronic bronchitis models, Chonluten reduced goblet cell hyperplasia and restored normal mucus rheological properties.
• Infection Susceptibility: Age-related decline in sIgA and antimicrobial peptide production increases respiratory infection frequency. Chonluten addresses this mucosal immunodeficiency.
• Asthma Research: Normalization of bronchial epithelial barrier function may reduce allergen penetration and submucosal immune activation in allergic airway disease models.
• Combination: Paired with Bronchogen for comprehensive respiratory bioregulator protocols—Bronchogen for tissue/structural support, Chonluten for mucosal immune defense.
• Protocol: 1–2 capsules daily for 20–30 days. Seasonal courses recommended, particularly during autumn and winter respiratory infection seasons.